On the fly News and insights, exclusive to thefly.com

MRK

Merck

$77.15 /

-1.18 (-1.51%)

, AVIR

Atea Pharmaceuticals

$40.58 /

+1.17 (+2.97%)

07:28
10/19/21
10/19
07:28
10/19/21
07:28

Merck rises 2% after Atea Covid drug fails in Phase 2 study

Shares of Merck (MRK) after up 2% to $78.94 in premarket trading after Atea Pharmaceuticals (AVIR) reported that AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate Covid compared to placebo. Merck's and Ridgeback Biotherapeutics' molnupiravir is currently under review at the Food and Drug Administration, and, if authorized, it will be the first oral antiviral to treat Covid patients in the U.S.

MRK

Merck

$77.15 /

-1.18 (-1.51%)

AVIR

Atea Pharmaceuticals

$40.58 /

+1.17 (+2.97%)

  • 24

    Oct

  • 28

    Oct

  • 08

    Nov

  • 28

    Nov

  • 04

    Dec

  • 10

    Dec

  • 21

    Dec

  • 21

    Mar

  • 28

    Mar

  • 30

    Oct

MRK Merck
$77.15 /

-1.18 (-1.51%)

10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/13/21 Citi
FDA likely to approve Merck EUA for molnupiravir, says Citi
10/12/21 Morgan Stanley
Merck price target raised to $88 from $85 at Morgan Stanley
AVIR Atea Pharmaceuticals
$40.58 /

+1.17 (+2.97%)

10/18/21 JPMorgan
Atea Pharmaceuticals price target raised to $61 from $56 at JPMorgan
10/05/21 Morgan Stanley
Atea downgraded to Equal Weight at Morgan Stanley following molnupiravir rally
10/05/21 Morgan Stanley
Atea downgraded to Equal Weight from Overweight at Morgan Stanley
09/09/21 SVB Leerink
Atea Pharmaceuticals initiated with an Outperform at SVB Leerink

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.